/PRNewswire/ According to the latest report published by Growth Plus Reports, the global radiopharmaceuticals market is expected to clock US$ 10.83 billion.
Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New Jersey . | May 5, 2022
FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2.